Durrant, Lindy G.

Human Leukocyte Antigen Class I, MHC Class I Chain-Related Molecule A, and CD8+/Regulatory T-Cell Ratio: Which Variable Determines Survival of Cervical Cancer Patients?

Jordanova, E. S., Gorter, A., Ayachi, O., Prins, F., Durrant, L. G., Kenter, G. G., van der Burg, S. H., & Fleuren, G. J. (2008) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersCervical Cancer and HPV Research

Cited by 233

Cancer Vaccines, Adjuvants, and Delivery Systems

Paston, S. J., Brentville, V. A., Symonds, P., & Durrant, L. G. (2021) · Frontiers in Immunology

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 200

NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting

McGilvray, R. W., Eagle, R. A., Watson, N. F. S., Al-Attar, A., Ball, G., Jafferji, I., Trowsdale, J., & Durrant, L. G. (2009) · Clinical Cancer Research

Immune Cell Function and InteractionCancer Immunotherapy and Biomarkers

Cited by 196

Citrullinated Vimentin Presented on MHC-II in Tumor Cells Is a Target for CD4+ T-Cell–Mediated Antitumor Immunity

Brentville, V. A., Metheringham, R. L., Gunn, B., Symonds, P., Daniels, I., Gijon, M., Cook, K., Xue, W., & Durrant, L. G. (2016) · Cancer Research

Immunotherapy and Immune ResponsesT-cell and B-cell Immunology

Cited by 98

Post-translational modifications such as citrullination are excellent targets for cancer therapy

Brentville, V. A., Vankemmelbeke, M., Metheringham, R. L., & Durrant, L. G. (2020) · Seminars in Immunology

Immunotherapy and Immune ResponsesT-cell and B-cell Immunology

Cited by 53